Market Digest Lowes Aptiv and Zoetis in Focus Leonardo Secures 320 Million Deal to Equip Kuwaiti Patrol Vessels Fed Chair Powell Vows No Shadow Chair Role But Clash with Kevin Warsh May Be Inevitable Bath Body Works Appoints Company Insider as Interim CFO UK Energy Policy Under Scrutiny Ministerial MiniMeasures May Not Address Structural Vulnerabilities Wall Street Analysts Maintain Cautiously Optimistic View on Ameriprise Financial CTAS Q1 2026 Earnings EPS Misses Estimates Stock Sees Modest Gain Chesapeake Utilities Corporation Q1 2026 Earnings Earnings Beat Expectations Stock Slips Slightly Reeds Inc REED Q1 2026 Earnings WiderthanExpected Loss Sends Stock Higher XRX Q1 2026 Earnings EPS Misses Estimates Amid Restructuring Stock Rises 98 ATA Creativity Global American Depositary Shares Q3 2024 Earnings EPS Reflects Continuing Losses Amid Speculative Stock Movement CPK Q1 2026 Earnings Earnings Beat Estimates as Utility Segment Drives Strong Results Integrated Media Technology IMTE Shows Resilience with 365 Gain Key Support and Resistance Levels in Focus Kayne Anderson Energy Infrastructure Fund KYN Edges Lower Key Levels in Focus MongoDB MDB Rises 27 as Bulls Test Key Resistance Near 34244 EMCOR Group EME Rises 17 Resistance Test Looms as Momentum Builds Fonar Corporation FONR Shows Modest Uptick Amid Steady Support Levels Nvidia Earnings Call in Focus Geopolitical Commentary and China Chip Strategy After Xi Summit EEOC May End Longstanding Employee Demographic Data Collection Sparking Debate on AntiDiscrimination Efforts Nexpace Launches NXPC Buyback Program to Support UserDriven Growth in MapleStory Universe TrumpXi Summit The 3 Big Takeaways from Historic Meeting in Beijing US Stocks Slide as AI Infrastructure Rout Intensifies Following Chinas DeepSeek Release NVCT Q1 2026 Earnings BetterthanExpected Loss Narrower as Company Advances Pipeline Avista Healthcare Partners and Damier Group Acquire sanotact Group with Legal Counsel from White Case VLN Q1 2026 Earnings NarrowerThanExpected Loss Drives Share Rally Sarepta Therapeutics SRPT Edges Higher Amid Modest Gains